Today, the U.S. Food and Drug Administration (FDA) approved LEQSELVI™ (deuruxolitinib) for alopecia areata, marking the third FDA-approved treatment for this disease. “It is with tremendous excitement that we welcome the FDA’s approval of a third treatment for severe alopecia areata in as many years,” said Nicole Friedland, President and CEO of the National Alopecia Areata Foundation (NAAF). “NAAF’s vision is an empowered community with a choice to embrace or live free of alopecia areata. Today’s announcement adds another effective treatment option for alopecia areata patients. NAAF celebrates this significant step forward and remains resolute in the commitment to research and treatment development advances for the benefit of the alopecia areata community.” LEQSELVI™ (deuruxolitinib) belongs to a class of medications known as Janus kinase (JAK) inhibitors. LEQSELVI™ is approved by the FDA for adults with severe alopecia areata. LEQSELVI™, from manufacturer Sun Pharmaceutical Industries, Ltd., is available by prescription only. The National Alopecia Areata Foundation (NAAF) drives research to find a cure and accessible treatments for alopecia areata, supports those impacted, and educates the public about the disease. Alopecia areata is a common autoimmune disease affecting nearly 7 million Americans that results in unpredictable, often sudden, and severe hair loss. Frequently dismissed as a cosmetic condition, alopecia can be a deeply traumatic experience, resulting in emotional and economic pain and social isolation. It is not just hair. Founded in 1981, NAAF is the largest alopecia areata patient advocacy organization in the world, connecting members of the alopecia areata community, including those living with the disease, family members and caregivers, healthcare providers, and researchers through its many programs. NAAF is recognized by the Internal Revenue Service as a 501(c)(3) charitable organization and has achieved the highest rankings from charity watchdogs including Candid, Charity Navigator, the Better Business Bureau’s Wise Giving Alliance and the National Health Council. For more information, please visit www.naaf.org, email info@naaf.org, or connect with NAAF on Facebook, Twitter, Instagram, and LinkedIn. Read Sun Pharma’s press release here. Learn more: Read more at LEQSELVI.com. Read about available treatments for alopecia areata. Read more about clinical trial data on deuruxolitinib.
